Retuers Novavax’s (NVAX.O), opens new tab experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots against the viruses in a late-stage trial.
Both the vaccine candidates were well tolerated with no new safety concerns, the biotech said on Wednesday. The study, which involved about 2,000 participants, tested the safety and immune response of the COVID-influenza combination and standalone flu vaccines compared to its COVID-19 shot Nuvaxovid and Sanofi’s (SASY.PA)
, opens new tab flu shot Fluzone HD, respectively.